Literature DB >> 12878473

An overview of endothelin signaling in the cardiac myocyte.

Peter H Sugden1.   

Abstract

Three endothelin (ET) isopeptides have been identified: ET-1, ET-2 and ET-3. These have two well-established gross effects on the cardiac myocyte. They affect the contractile properties and they stimulate myocyte growth and myofibrillogenesis. There may be other effects that are less fully characterized (e.g. increased resistance apoptosis). The changes in myocyte biology are brought about by modulation of intracellular signaling pathways. ET-1 binds to the ET(A) receptor on the cell surface and stimulates hydrolysis of phosphatidylinositol 4', 5'-bisphosphate to diacylglycerol and inositol 1', 4', 5'-trisphosphate. Diacylglycerol remains in the plane of the membrane and this causes translocation of the delta- and epsilon-isoforms of protein kinase C (PKC) to that compartment, an event thought to be indicative of PKC activation. The next events (probably associated with PKC activation) are the activation of the small G-protein Ras and of the extracellular signal-regulated kinase 1/2 (ERK1/2) cascade. Over a longer time course, two protein kinase cascades related to the ERK1/2 cascade, the c-Jun N-terminal kinase and p38-mitogen-activated protein kinase (p38-mitogen) cascades, also become activated. As the signals originating from the ET(A) receptor are transmitted through these protein kinase pathways, other signaling molecules become phosphorylated, thus changing their biological activity. Such molecules include nuclear transcription factors (e.g. GATA-4, c-Jun), protein kinases (e.g. 90-kDa ribosomal protein S6 kinase, MAPK-activated protein kinase 2), and ion exchangers/channels (e.g. the Na(+)/H(+) exchanger 1). These changes are responsible for the overall biological effects of ET isopeptides on the myocyte.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12878473     DOI: 10.1016/s0022-2828(03)00153-6

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  46 in total

1.  Evidence for calreticulin attenuation of cardiac hypertrophy induced by pressure overload and soluble agonists.

Authors:  Sylvia Papp; Ewa Dziak; Golam Kabir; Peter Backx; Sophie Clement; Michal Opas
Journal:  Am J Pathol       Date:  2010-01-28       Impact factor: 4.307

2.  Novel function of cardiac protein kinase D1 as a dynamic regulator of Ca2+ sensitivity of contraction.

Authors:  Mariah H Goodall; Robert D Wardlow; Rebecca R Goldblum; Andrew Ziman; W Jonathan Lederer; William Randall; Terry B Rogers
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

3.  The cardiac IP3 receptor: uncovering the role of "the other" calcium-release channel.

Authors:  Thomas J Hund; Andrew P Ziman; W J Lederer; Peter J Mohler
Journal:  J Mol Cell Cardiol       Date:  2008-06-13       Impact factor: 5.000

4.  Moving into a new neighborhood: NOS goes nuclear.

Authors:  Mark T Ziolo; Brandon J Biesiadecki
Journal:  J Mol Cell Cardiol       Date:  2013-06-22       Impact factor: 5.000

5.  ZFP260 is an inducer of cardiac hypertrophy and a nuclear mediator of endothelin-1 signaling.

Authors:  Hiba Komati; Wael Maharsy; Janie Beauregard; Salim Hayek; Mona Nemer
Journal:  J Biol Chem       Date:  2010-11-04       Impact factor: 5.157

6.  Ca2+ oscillation frequency decoding in cardiac cell hypertrophy: role of calcineurin/NFAT as Ca2+ signal integrators.

Authors:  Matilde Colella; Francesca Grisan; Valerie Robert; Jay D Turner; Andrew P Thomas; Tullio Pozzan
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

7.  ERK1/2 signaling dominates over RhoA signaling in regulating early changes in RNA expression induced by endothelin-1 in neonatal rat cardiomyocytes.

Authors:  Andrew K Marshall; Oliver P T Barrett; Timothy E Cullingford; Achchuthan Shanmugasundram; Peter H Sugden; Angela Clerk
Journal:  PLoS One       Date:  2010-04-02       Impact factor: 3.240

8.  PKA, Rap1, ERK1/2, and p90RSK mediate PGE2 and EP4 signaling in neonatal ventricular myocytes.

Authors:  Quan He; Pamela Harding; Margot C LaPointe
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-10-30       Impact factor: 4.733

Review 9.  Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure.

Authors:  Navneet S Rehsia; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2010-01       Impact factor: 4.214

10.  Proteomics analysis of the cardiac myofilament subproteome reveals dynamic alterations in phosphatase subunit distribution.

Authors:  Xiaoke Yin; Friederike Cuello; Ursula Mayr; Zhiqi Hao; Martin Hornshaw; Elisabeth Ehler; Metin Avkiran; Manuel Mayr
Journal:  Mol Cell Proteomics       Date:  2009-12-27       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.